摘要
我国"十四五"规划将生物技术列为战略性新兴产业,明确从国家急迫需要和长远需求出发,集中优势资源攻关新发突发传染病和生物安全风险防控,医药和医疗设备等领域关键核心技术。相较其他科研建筑,生物医药类建筑因其涉及实验的复杂性与危险性,故设计要求更具特殊性。以国药北京生物203号研发大楼为例,分析其总体规划、体块生成、功能布局和建筑结构,探讨其对生物医药行业转型升级的促进意义,为未来生物医药类建筑设计提供参考。
China's K14th Five-Year Plan"lists biotechnology as a strategic emerging industry,clearly starting from the urgent needs and long-term needs of the country,and concentrating superior resources to tackle key core tech no logies in the fields of emergi ng infectious diseases and biosecurity risk prevention and control,medicine and medical equipment.Compared with other scientific research buildings,biomedical buildings have more special design requirements because of the complexity and dan ger of the experime nts involved.Taking SINOPHARM Beijing Biotech No.203 research and development building as an example,analyzing its overall planning,mass generation,functional layout and building structure,discusses its significance in promoting the transformation and upgrading of the biomedical industry,and provides reference for future biomedical architectural design.
作者
黄国磊
梁志刚
孙军伟
史金娜
HUANG Guolei;LIANG Zhigang;SUN Junwei;SHIJinna
出处
《城市建筑空间》
2023年第3期2-7,共6页
Urban Architecture Space
关键词
建筑设计
生物医药
科研楼
轴线回应
architectural design
biomedicine
research and development building
axis response
作者简介
黄国磊,中国城市建设研究院有限公司建筑院副总工程师,高级建筑师,国家一级注册建筑师;梁志刚,中国城市建设研究院有限公司市场经营中心副总经理,广西分院院长,高级建筑师;孙军伟,中国城市建设研究院有限公司广西分院综合二所所长,高级工程师;史金娜,中国城市建设研究院有限公司广西分院综合二所设计师,高级建筑师。
